Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03338595 · ClinicalTrials.gov registry record

Longitudinal Assessment of Exercise Capacity and Vascular Function in Patients With CF

A clinical trial of Cystic Fibrosis, sponsored by Augusta University.

Completed
Registry status
20
Enrollment target
1
Study location

NCT03338595: Completed study of Cystic Fibrosis, sponsored by Augusta University.

NCT03338595 is a study of Cystic Fibrosis that has completed, run by Augusta University. The registered enrollment target is 20 participants, below the 179-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03338595, a study of Cystic Fibrosis, has completed, sponsored by Augusta University.

COMPLETED
Registry status
20 participants
Enrollment target
1
Study location

Study Summary

This project is an attempt to understand how Orkambi treatment affects exercise capacity and the function of the arteries in CF patients who are homozygous F508del. Our goal is to perform the exercise and vascular measurements every 3 months after a patient starts taking Orkambi.

Primary Outcome

Subjects will perform the maximal exercise tests on an electronically braked cycle ergometer using the Godfrey protocol. Expired gases will be collected using a Parvo Medics True One metabolic cart for determination of exercise capacity (VO2 peak).

Conditions Studied

Study Locations (1)

Georgia

  • Georgia Prevention Institute - Augusta

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2014-05
Est. Completion 2020-10
Augusta University

106 total trials

What the finished NCT03338595 record still lists

NCT03338595 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 179-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (89% lower).

The record links to 1 condition, with Cystic Fibrosis appearing as the primary indexed condition, and to 0 interventions.

NCT03338595 reports a single indexed study location in Georgia.

Frequently Asked Questions

What is clinical trial NCT03338595 about?

NCT03338595 is a clinical study titled "Longitudinal Assessment of Exercise Capacity and Vascular Function in Patients With CF". This project is an attempt to understand how Orkambi treatment affects exercise capacity and the function of the arteries in CF patients who are homozygous F508del. Our goal is to perform the exercise and vascular measurements every 3 months after a patient starts taking Orkambi.

What is the current status of trial NCT03338595?

This trial is currently completed. The enrollment target is 20 participants. The study started on 2014-05. Estimated completion is 2020-10.

What conditions does trial NCT03338595 study?

This clinical trial studies the following conditions: Cystic Fibrosis.

Who is sponsoring clinical trial NCT03338595?

This trial is sponsored by Augusta University, which has 106 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03338595 being conducted?

This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cystic Fibrosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03338595's enrollment target sits among peer trials

20 130th of 169 higher than 38 of 169 other Cystic Fibrosis trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Cystic Fibrosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00573339 · 20 participants

    Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing

  • NCT00692939 · 20 participants · Phase 1

    Autologous Stem Cell Transplantation for Crohn's Disease

  • NCT00967785 · 20 participants · Phase 1

    A Phase I Study of Mozobil in the Treatment of Patients With WHIMS

  • NCT01406691 · 20 participants · Phase 4

    Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT03338595, the US trial registry maintained by the National Library of Medicine. NCT03338595 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.